Effects of Curcumin and Telmisartan on Olanzapine and high fructose diet induced Metabolic Syndrome in Spraugue Dawly Rats

Abstract

Objective: To study the effects of curcumin and telmisartan on olanzapine, high fructose diet (HFD) and both olanzapine and HFD-induced metabolic syndrome. Method: Adult male Spraugue Dawly (SD) rats were used for the study. Animals were divided into ten groups including normal and HFD controls. The obesity/metabolic syndrome was induced using olanzapine (1 mg/kg; i.p.), a second generation antipsychotic and HFD. Effect of curcumin (50 mg/kg; p.o.) and telmisartan (5 mg/kg; p.o.) on olanzapine, HFD and both olanzapine and HFD-induced metabolic syndrome. All drugs were administered for 28 days. The blood sample was collected through retro orbital sinus and the plasma was separated at the end of study. The plasma sample was used to estimate the biochemical parameters such as blood glucose, aspartate aminotransferase (ALT ), alanine aminotransferase (ALT ), urea, uric acid, creatinine, total cholesterol, triglyceride; and high-density lipoprotein (HDL) levels were analyzed and the low-density lipoprotein (LDL) levels were calculated using Frieldwann's equation. After completing the experiment, all experimental animals were sacrificed by cervical dislocation and their organs such as heart, liver, kidney and peritoneal fat pads were removed and the absolute organ weight was measured. Result: The animals treated with olanzapine and fed with HFD showed significant increase in body weight and biochemical parameters when compared to the control group. Curcumin and telmisartan were significantly (P<0.001) inhibited, the HFD and olanzapine induced increase in body weight and also brought the biochemical levels to normal when compared to the olanzapine and HFD groups, respectively. The animals treated with telmisartan showed significant inhibition on the liver weight and peritoneal fat levels when compared to control group. Conclusion: The study results suggested that curcumin and telmisartan significantly inhibited the olanzapine and HFD-induced metabolic syndrome. Telmisartan affects the total lipid profile, glucose metabolism and decreases the body weight.